NR vs NMN: NAD+ Precursors for Brain Aging, Reviewed Honestly

What NAD+ actually is and why it matters

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme required for hundreds of enzymatic reactions in every cell. Its critical roles:

• Cellular energy metabolism: NAD+ is essential for glycolysis, the Krebs cycle, and electron transport chain function — the pathways that produce ATP
• Sirtuin activation: NAD+ is required for sirtuin enzyme activity. Sirtuins regulate DNA repair, mitochondrial function, and cellular stress responses. This is the mechanism at the center of David Sinclair's aging research.
• PARP DNA repair: Poly(ADP-ribose) polymerases use NAD+ to repair single-strand DNA breaks. High DNA damage load depletes NAD+.
• CD38 activity: immune cells use NAD+ via the CD38 enzyme, contributing to age-related NAD+ decline

NAD+ levels in most tissues (including brain) decline substantially with age — by roughly 50% between age 40 and 60 in many measurements.^[1] This decline correlates with metabolic dysfunction, reduced mitochondrial capacity, and impaired cellular repair. The therapeutic hypothesis: restore NAD+ levels, restore some aspects of youthful cellular function.

How NR and NMN differ

Both are NAD+ precursors — molecules that get converted to NAD+ inside cells. They're related structurally: NMN is essentially NR with an additional phosphate group.

Nicotinamide riboside (NR) is a form of vitamin B3 discovered in the early 2000s by Charles Brenner. NR enters cells directly via nucleoside transporters, gets phosphorylated to NMN inside the cell, then converted to NAD+.

Nicotinamide mononucleotide (NMN) is the immediate precursor to NAD+ in the salvage pathway. The debate about NMN: does it enter cells intact, or does it get dephosphorylated to NR at the cell surface, enter the cell as NR, and get re-phosphorylated inside? Some evidence suggests a specific NMN transporter (Slc12a8) exists but its role is disputed.

Practically, both compounds reliably raise blood and tissue NAD+ levels in animal and human studies. Whether they do so through the same or different intracellular pathways is scientifically important but not necessarily practically relevant for the consumer.

The human clinical evidence — what's actually been shown

NR raises blood NAD+ (Trammell 2016) — the first human PK study of NR (Niagen) showed dose-dependent increases in blood NAD+ over 24 hours after single oral doses of 100-1,000 mg. Chronic dosing showed sustained NAD+ elevation.^[2]

NR for cardiovascular function (Martens 2018) — 24 healthy middle-aged and older adults took 500 mg NR twice daily or placebo for 6 weeks. NR reduced systolic blood pressure by 7 mmHg in the subgroup with elevated baseline BP (borderline stage 1 hypertension). Aortic stiffness decreased. NAD+ blood levels approximately doubled.^[3]

NR for metabolic health (Dollerup 2018) — 40 men with obesity and insulin resistance took 1,000 mg NR twice daily or placebo for 12 weeks. NAD+ rose. Insulin sensitivity, glucose control, and other metabolic markers did NOT significantly improve. This was a well-designed trial with a negative result on the primary metabolic endpoints.^[4]

NMN in postmenopausal women (Yoshino 2021) — 25 prediabetic postmenopausal women took 250 mg NMN daily or placebo for 10 weeks. Insulin sensitivity in skeletal muscle improved significantly in the NMN group vs placebo. This is one of the more promising NMN clinical results but a small trial.^[5]

NMN in older adults (Igarashi 2022) — 42 healthy older men took 250 mg NMN in the morning or afternoon or placebo for 12 weeks. NAD+ rose. Physical performance (grip strength, gait speed) showed subtle improvements. No effects on sleep, mood, or cognitive endpoints measured.^[6]

NR for Parkinson's disease (Brakedal 2022) — 30-day pilot of 1,000 mg NR daily in early Parkinson's patients showed increased brain NAD+ on MRS imaging and improvements on the Unified Parkinson's Disease Rating Scale. Small trial, no true placebo control.^[7]

What hasn't been shown yet

The mismatch between marketing claims and clinical data is worth naming clearly. What NR and NMN have not been shown to do in published human trials:

• Extend lifespan (impossible to study directly in humans without decades of data)
• Reverse cognitive aging in healthy adults
• Prevent Alzheimer's disease or other neurodegenerative conditions
• Meaningfully improve muscle mass or strength in healthy older adults
• Reverse mitochondrial dysfunction to youthful levels in clinical terms
• Produce broad "younger" biological markers on multi-marker aging scores

Some of these claims come directly from David Sinclair's public communications, others from supplement marketing that leverages his profile. The molecular biology and animal work are legitimately interesting. The human clinical translation, so far, has produced modest and specific improvements — nothing close to the transformative anti-aging narrative in popular coverage.

Being honest about this doesn't mean these compounds are worthless. Reliably raising NAD+ is a real effect. The clinical benefit likely exists but is probably: 1) modest, 2) most pronounced in populations with specific dysfunction (metabolic, cardiovascular, potentially neurological), and 3) requires more research to characterize properly.

Dosing and forms

Both compounds are generally well-tolerated at these doses. Highest-quality NR is sold as Niagen (branded, Chromadex-manufactured). Generic NR exists at lower price points. NMN has more variable market quality — the compound is unstable and some products degrade quickly.

The trimethylglycine (TMG) methyl-donor question: Both NR and NMN increase demand for methyl groups (used to break down nicotinamide byproducts). Some protocols recommend TMG (betaine) alongside NR/NMN at 500-1,000 mg to prevent methyl-donor depletion. The clinical evidence for this is thin but the mechanistic logic is sound.

Who benefits, who should skip

NR or NMN may be worth considering for:

• Adults 50+ with elevated cardiovascular risk (BP, aortic stiffness) — NR has the specific Martens data
• Prediabetic postmenopausal women — NMN has Yoshino data
• Early Parkinson's patients under neurology guidance — NR has emerging Brakedal data
• People with financial resources to run their own quasi-experiments and reasonable skepticism about outcomes

Skip or wait if:

• You're expecting dramatic anti-aging or cognitive effects — the human data doesn't support these claims
• Budget is limited — NR runs $30-80/month, NMN $40-100/month. For that money, well-established supplements (citicoline, omega-3, Magtein, ashwagandha) have stronger evidence for defined outcomes
• You have active cancer — some concerns about NAD+ elevation supporting cancer cell metabolism; coordinate with oncologist
• You're pregnant or breastfeeding (insufficient safety data)

The Sinclair skepticism note

David Sinclair is a real Harvard aging researcher with legitimate scientific contributions. He's also actively involved in supplement companies (formerly Elysium Health, currently others), regularly makes claims about his own supplement use that go substantially beyond the published evidence, and has been criticized by peer aging researchers for public communications that oversell the current human evidence.

None of this means his underlying science is wrong. It does mean that "Sinclair takes it" is not the same as "the evidence supports it." Charles Brenner (the NR discoverer, now at City of Hope) is a useful counter-voice — his social media and interviews consistently push back on Sinclair-adjacent overclaims while acknowledging the legitimate underlying biology.

The honest position for consumers: NR and NMN are real supplements with real effects on measurable biomarkers. The clinical translation is early and modest. If you buy them, buy them for the specific published effects (BP support with NR, potential insulin sensitivity with NMN) — not for the anti-aging or cognitive claims that outrun current evidence.